Zyprexa marketing documents subpoenaed in Florida
Executive Summary
Lilly says it is complying with a request from the Florida Attorney General's Medicaid Fraud Control Unit for documents relating to sales, marketing and promotional practices for Zyprexa; other Lilly products could become subject to investigation, company's 10-Q filing states. Lilly says subpoena is unrelated to removal of Zyprexa and Symbyax from the state's Medicaid preferred drug list (1"The Pink Sheet" July 11, 2005, p. 11)...